Product Portfolio


Allergies and asthma are among the most common chronic conditions globally, ranging from manageable to life-threatening. Allergies in particular are on the rise: in 2015 close to 50% of the world population was affected by some form of allergy, while severe allergic reactions (anaphylaxis) have increased several-fold in the past decade. 

Allergic rhinitis is one form of allergy and is considered a global epidemic, affecting some 500 million people worldwide, of which around 180 million are in Western Europe, US and Japan. The disease is associated with high socioeconomic costs.

Asthma is a chronic condition affecting the respiratory tract and lungs. It narrows the airways to the lungs due to inflammation in the air passages, resulting from both generic and environmental influences. It is the most common chronic disease among children and an estimated 300 million individuals worldwide are affected. 

The cornerstone in asthma therapy is effectively treating the underlying chronic inflammation with inhaled corticosteroids while minimizing systemic exposure. Optimal drug delivery to the lungs is therefore of paramount importance and can be facilitated by spacers. US asthma guidelines have recommended using a spacer for inhaled corticosteroid therapy.

Key Products in Respiratory


Allergic rhinitis has become more difficult to treat in recent years. More than two thirds of the patients have moderate to severe allergic rhinitis. They are more likely than in the past to be sensitive to multiple allergens, and around 20% of them show greater resistance to therapy. There is an unmet medical need for more effective therapy, in particular since studies have shown that many patients continue to suffer even during and after their treatment with existing therapies. Dymista is a novel nasal spray that contains the active ingredients azelastine and fluticasone. The formulation contributes to the product profile. Dymista’s efficacy and safety were documented in several studies involving more than 4,600 patients. The drug is faster and more effective than the first line therapy (azelastine hydrochloride and fluticasonepropionate) for patients with moderately severe to severe seasonal allergic rhinitis. It can thus provide more moderate to severe allergic rhinitis patients with substantial or complete symptom relief. Dymista was launched in the second half of 2012 in the US and was launched in Europe in 2013 and quickly captured a significant share of several important markets. Dymista is now being rolled out in Emerging Markets.


In 2013 Meda acquired Aerospan which allows Meda to market the only inhaled corticosteroid (ICS) treatment containing an integrated spacer. This feature ensures consistent and targeted delivery to the lungs for the treatment of asthma. External inhalation spacers are commonly used in clinical practice and are recommended for use with metered dose inhalers in the US and in international treatment guidelines. Aerospan is an inhaled corticosteroid which is indicated for the maintenance treatment of asthma in patients six years of age and older, and for asthma patients requiring oral corticosteroid therapy, where adding Aerospan inhalation aerosol may reduce or eliminate the need for oral corticosteroids. Aerospan was launched in the US in the beginning of the second quarter 2014. This will allow the company to continue to grow in the respiratory field, addressing upper and lower airway conditions with its spectrum of products.


Anaphylaxis (anaphylactic shock) occurs when the body’s immune system overreacts to a substance, such as a food item. It is an unpredictable condition that can be life threatening. EpiPen is an adrenaline auto-injector used for the acute treatment of anaphylactic shock or severe allergic reactions to allergens, e.g. insect bites or foods. Meda has received a label extension for EpiPen and the product is now also intended for immediate administration in patients who are determined to be at increased risk of anaphylaxis (including patients with a history of anaphylactic reactions). People at risk of anaphylactic shock should always carry an adrenaline injector. The at-risk indication is further endorsed by the new guidelines of the European Academy of Allergy and Clinical Immunology (EAACI).


Azelastine is a nasal spray for the treatment of allergic and non-allergic rhinitis. It contains the active ingredient azelastine which is an antihistamine. In China it is marketed under the brand Azep, and is a fast growing brand in allergic rhinitis. In Europe, Azep is marketed under the brands Allergodil and Rhinolast. In the US market the Azelastine trademark Astelin has largely been replaced by the life cycle product Astepro.


Astepro is a nasal spray used for the treatment of allergic and non-allergic rhinitis. It contains the active ingredient azelastine, which is an antihistamine. Astepro is an improved formulation of Azelastine (Azep, Astelin, Allergodil and Rhinolast) which is better tolerated and more effective. Once-daily Astepro is the first nasal antihistamine approved as a single dose for patients with seasonal allergies. The registration process is ongoing in other important markets.

Novopulmon Novolizer

Novolizer is an innovative dry powder inhaler used to administer the active substances salbutamol (albuterol), formoterol and budesonide for the treatment of asthma and chronic obstructive pulmonary disease.

Formatris Novolizer

The active ingredient in Formatris Novolizer is formoterol, a bronchodilator or long acting beta agonist. Formatris Novolizer is used for the treatment of asthma and COPD. Like Novopulmon, Formatris Novolizer is delivered via Novolizer, a dry powder inhaler. 


Pafinur is an antihistamine used to treat various forms of allergies including allergic rhinitis. Sales of Pafinur are primarily generated in Italy where the molecule, rupatadine, is patented.

Other respiratory products


Fortilase (Cx)

Ialumar (Cx)


This website is intended for people seeking information on Meda AB's Global operations.
We also have national marketing sites. Links to these are under Meda Worldwide at the top of the page.